Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 2
2005 3
2006 3
2009 1
2010 1
2011 1
2012 3
2013 2
2014 2
2015 2
2016 4
2017 4
2018 4
2019 2
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Results by year
Filters applied: . Clear all
Page 1
GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism.
Mondragón L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, Pons C, Chiche J, Jacquin M, Imbert V, Proïcs E, Boyer L, Doye A, Luciano F, Neels JG, Coutant F, Fabien N, Sormani L, Rubio-Patiño C, Bossowski JP, Muller F, Marchetti S, Villa E, Peyron JF, Gaulard P, Lemonnier F, Asnafi V, Genestier L, Benhida R, Fournié JJ, Passeron T, Ricci JE, Verhoeyen E. Mondragón L, et al. Among authors: peyron jf. Cancer Cell. 2019 Sep 16;36(3):268-287.e10. doi: 10.1016/j.ccell.2019.07.008. Epub 2019 Aug 22. Cancer Cell. 2019. PMID: 31447347 Free article.
Withdrawal: Hepatitis C virus NS5A and subgenomic replicon activate NF- κ B via tyrosine phosphorylation of I κ B α and its degradation by calpain protease.
Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A. Waris G, et al. Among authors: peyron jf. J Biol Chem. 2018 Dec 28;293(52):20012. doi: 10.1074/jbc.W118.007016. J Biol Chem. 2018. PMID: 30593533 Free PMC article. No abstract available.
Mitochondrial Transfer in the Leukemia Microenvironment.
Griessinger E, Moschoi R, Biondani G, Peyron JF. Griessinger E, et al. Among authors: peyron jf. Trends Cancer. 2017 Dec;3(12):828-839. doi: 10.1016/j.trecan.2017.10.003. Epub 2017 Nov 6. Trends Cancer. 2017. PMID: 29198439 Review.
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.
Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E. Moschoi R, et al. Among authors: peyron jf. Blood. 2016 Jul 14;128(2):253-64. doi: 10.1182/blood-2015-07-655860. Epub 2016 Jun 2. Blood. 2016. PMID: 27257182
NF-κB in Hematological Malignancies.
Imbert V, Peyron JF. Imbert V, et al. Among authors: peyron jf. Biomedicines. 2017 May 31;5(2):27. doi: 10.3390/biomedicines5020027. Biomedicines. 2017. PMID: 28561798 Free PMC article. Review.
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Muselli F, Peyron JF, Mary D. Muselli F, et al. Among authors: peyron jf. Int J Mol Sci. 2019 Nov 10;20(22):5616. doi: 10.3390/ijms20225616. Int J Mol Sci. 2019. PMID: 31717629 Free PMC article. Review.
Targeting the Human 80S Ribosome in Cancer: From Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies.
Gilles A, Frechin L, Natchiar K, Biondani G, Loeffelholz OV, Holvec S, Malaval JL, Winum JY, Klaholz BP, Peyron JF. Gilles A, et al. Among authors: peyron jf. Cells. 2020 Mar 5;9(3):629. doi: 10.3390/cells9030629. Cells. 2020. PMID: 32151059 Free PMC article. Review.
Metformin, an Anti-diabetic Drug to Target Leukemia.
Biondani G, Peyron JF. Biondani G, et al. Among authors: peyron jf. Front Endocrinol (Lausanne). 2018 Aug 10;9:446. doi: 10.3389/fendo.2018.00446. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30147674 Free PMC article. Review.
Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA.
Thongon N, Zucal C, D'Agostino VG, Tebaldi T, Ravera S, Zamporlini F, Piacente F, Moschoi R, Raffaelli N, Quattrone A, Nencioni A, Peyron JF, Provenzani A. Thongon N, et al. Among authors: peyron jf. Cancer Metab. 2018 Mar 8;6:1. doi: 10.1186/s40170-018-0174-7. eCollection 2018. Cancer Metab. 2018. PMID: 29541451 Free PMC article.
Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia.
Rosilio C, Ben-Sahra I, Bost F, Peyron JF. Rosilio C, et al. Among authors: peyron jf. Cancer Lett. 2014 May 1;346(2):188-96. doi: 10.1016/j.canlet.2014.01.006. Epub 2014 Jan 22. Cancer Lett. 2014. PMID: 24462823 Review.
37 results
Jump to page